KANRENOL ® is a drug based on potassium canrenoate
THERAPEUTIC GROUP: Diuretics / antialdosteronic diuretics
Indications KANRENOL ® Potassium canrenoate
KANRENOL ® is indicated in the treatment of edematous conditions of various origins, due to congestive heart failure, liver cirrhosis in the ascitic phase, nephrotic syndrome.
The antialdosteronic action of KANRENOL ® also guarantees a therapeutic efficacy in case of primary and secondary aldosteronism with consequent edema.
KANRENOL ® can also be used in the treatment of arterial hypertension when other therapies have not proved particularly effective.
Mechanism of action KANRENOL ® Potassium canrenoate
After oral administration, potassium canrenoate, active principle of KANRENOL ®, is effectively absorbed with a plasma peak of canrenone (active form of the active principle) around the third, fourth hour, and with a prolonged half-life for several hours.
At the renal level, canrenone is able to compete with aldosterone for binding to the respective receptors, expressed in the distal convoluted tubule and in the collecting duct. The competitive action takes the form of a reduction in the reabsorption of sodium and chlorine, saving potassium from urinary excretion. For this reason and for a therapeutic efficacy carried out even at low doses, potassium canrenoate is more suitable than other diuretics in therapeutic treatment over time.
At the end of its action, the canrenone is eliminated in equal parts in the kidney and intestine.
Studies carried out and clinical efficacy
1. POTASSIUM CANRENOATE AND CIRRUSIS VARES
Clin Gastroenterol Hepatol. 2006 Nov; 4: 1395-402. Epub 2006 Aug 22.
Effect of potassium canrenoate, an anti-aldosterone agent, on incidence of ascites and variceal progression in cirrhosis.
Bolondi L, Piscaglia F, Gatta A, Salerno F, Bernardi M, Ascione A, Ferraù O, Sacerdoti D, Visentin S, Trevisani F, Mazzanti R, Donati G, Arena U, Gentilini P; DOC (Decrease Of Complications in cirrhosis) Study Group.
120 patients with ascites were treated with potassium canrenoate at 100mg / day. Although the therapy was well tolerated and without clinically relevant side effects, the individual incidence of esophageal varices in treated patients was not reduced, while there was a decrease in the worsening of the conditions and in the accumulation of these events during one year of treatment.
2. POTASSIUM CANRENOATE AND ASCITE
Gut. 2010 Jan; 59: 98-104.
Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: results of an open randomized clinical trial.
Angeli P, Fasolato S, Mazza E, Okolicsanyi L, Maresio G, Velo E, Galioto A, Salinas F, D "Aquino M, Sticca A, Gatta A.
The study shows how potassium canrenoate therapy is effective for the treatment of the ascitic condition already at doses of 200mg / day. For patients unresponsive to this therapy, the dose was doubled and the concomitant furosemide was administered only later. The results obtained show that in almost 80% of the treated patients the administration of potassium canrenoate was sufficient, while the synergistic therapy was only necessary for a small group of non-responders.
3. CARDIOPROTECTIVE EFFECT OF ANTIALDOSTERONICS
Eur Heart J. 2010 Jul; 31: 1655-62. Epub 2009 Dec 21.
Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion.
Schmidt K, Tissier R, Ghaleh B, Drogies T, Felix SB, Krieg T.
Studies carried out on animal models of cardiac ischemia / reperfusion (typical condition during myocardial infarction), have shown a particular efficacy of antialdosterones in reducing induced tissue damage. This study suggests a possible use of antialdosterones for the treatment of acute infarction. myocardium.
Method of use and dosage
KANRENOL ® tablets of 25mg / 100mg / 200mg of potassium canrenoate: it is recommended to take 1 tablet per day, according to the type and severity of the pathological condition. The dosage, therefore, should necessarily be formulated by the doctor, after a "careful evaluation of the patient's physio-pathological conditions.
KANRENOL ® 200mg bottles of potassium canrenoate: it is recommended to take 1 - 3 bottles per day, by slow intravenous infusion or drip. Also in this case the specific dosage must be formulated by the doctor according to the patient's conditions, and the administration carried out by trained health personnel.
IN ANY CASE, BEFORE TAKING KANRENOL ® Potassium canrenoate - THE PRESCRIPTION AND CONTROL OF YOUR DOCTOR IS NECESSARY.
Warnings KANRENOL ® Potassium canrenoate
As for the other drugs belonging to this pharmacotherapeutic group, before proceeding with the intake of KANRENOL ® it would be advisable to check the blood levels of sodium, potassium and chlorine. The monitoring of these parameters should also be prolonged during the therapeutic intervention, with particular scrupulousness in patients undergoing surgery.
The particular biological action of canrenone, which saves potassium, makes it possible to avoid a diet rich in this trace element during the therapeutic process.
Pediatric use must be carried out under strict medical supervision and in case of real need.
The use of KANRENOL ® does not interfere with the normal ability to drive or use machines, however, unpredictable hypotensive episodes and possible especially in case of inadequate dosage, could reduce the patient's perceptive and reactive abilities.
PREGNANCY AND BREASTFEEDING
KANRENOL ® can be administered during pregnancy, only in case of real need and only under strict medical supervision. The property of the canrenone to be secreted with the mother's milk forces the mother to suspend breastfeeding during therapy.
Interactions
KANRENOL ® can interact with:
- Ganglyoplegics of various kinds, enhancing their effects;
- Hypertensive, with increased diuretic effect;
- Acetylsalicylic acid and derivatives, with a significant reduction in the diuretic efficacy of canrenone;
- Potassium salts, with possible hyperkalemia.
Contraindications KANRENOL ® Potassium canrenoate
KANRENOL ® is contraindicated in case of hypersensitivity to one of its components, in conditions of electrolyte imbalance (hyperkalaemia and hyponatremia), acute and chronic renal failure, and anuria.
Undesirable Effects - Side Effects
KANRENOL ®, if administered at therapeutic doses established on the real needs of the patient, is safer than diuretics of other nature, rarely recording side effects such as nausea, cramps, abdominal pain and drowsiness.
In case of hypersensitivity to one of the components of KANRENOL ® or in case of concomitant administration of structurally similar drugs, it is possible to observe temperature rises, gynecomastia, skin rashes, localized redness, menstrual irregularities and hirsutism. All of the aforementioned effects tend to subside once the therapy is discontinued.
Note
KANRENOL ® can only be sold under medical prescription.
The use of KANRENOL ® should always be done after consulting your doctor.
The indiscriminate use of KANRENOL ® among athletes and non-athletes, to search for the loss of a few kilos, exposes the body to serious side effects. Furthermore, it is always advisable to reiterate that weight loss is dictated by the elimination of liquids and salts and not by a real slimming effect, intended as a loss of fat mass.
Therefore KANRENOL ® is classified among the DOPING substances.
The information on KANRENOL ® Potassium canrenoate published on this page may be out of date or incomplete. For a correct use of this information, see the Disclaimer and useful information page.
